Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 1...
Main Authors: | Marie Jaspard, Nathalie Butel, Najoua El Helali, Dhiba Marigot-Outtandy, Helene Guillot, Gilles Peytavin, Nicolas Veziris, Bahram Bodaghi, Philippe Flandre, Gregoire Petitjean, Eric Caumes, Valerie Pourcher |
---|---|
Format: | Article |
Language: | English |
Published: |
Centers for Disease Control and Prevention
2020-08-01
|
Series: | Emerging Infectious Diseases |
Subjects: | |
Online Access: | https://wwwnc.cdc.gov/eid/article/26/8/19-1499_article |
Similar Items
-
Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
by: Marie Jaspard, et al.
Published: (2017-10-01) -
Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
by: Barbara Eker, et al.
Published: (2008-11-01) -
THE EFFECT OF DIFFERENT TB DRUGS AND ANTIMICROBIAL AGENTS ON THE EFFICIENCY OF TREATMENT OF TUBERCULOSIS PATIENTS WITH MULTIPLE DRUG RESISTANCE
by: I. A. Vasilyeva, et al.
Published: (2017-11-01) -
Extensively Drug-Resistant Tuberculosis, Central China, 2007–2009
by: Dawei Shi, et al.
Published: (2012-11-01) -
Beijing Lineage of MDR Mycobacterium tuberculosis in Bulgaria, 2007–2011
by: Stefan Panaiotov, et al.
Published: (2014-11-01)